| Literature DB >> 29902520 |
Zhining Wen1, Yu Liang1, Yingyi Hao1, Brian Delavan2, Ruili Huang3, Mike Mikailov4, Weida Tong5, Menglong Li6, Zhichao Liu7.
Abstract
Drug-induced rhabdomyolysis (DIR) is an idiosyncratic and fatal adverse drug reaction (ADR) characterized in severe muscle injuries accompanied by multiple-organ failure. Limited knowledge regarding the pathophysiology of rhabdomyolysis is the main obstacle to developing early biomarkers and prevention strategies. Given the lack of a centralized data resource to curate, organize, and standardize widespread DIR information, here we present a Drug-Induced Rhabdomyolysis Atlas (DIRA) that provides DIR-related information, including: a classification scheme for DIR based on drug labeling information; postmarketing surveillance data of DIR; and DIR drug property information. To elucidate the utility of DIRA, we used precision dosing, concomitant use of DIR drugs, and predictive modeling development to exemplify strategies for idiosyncratic ADR (IADR) management. Published by Elsevier Ltd.Entities:
Mesh:
Year: 2018 PMID: 29902520 PMCID: PMC7050640 DOI: 10.1016/j.drudis.2018.06.006
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851